For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 1,435,135 | 2,924,607.5* | 2,131,444 | 3,724,755 |
| General and administrative | 1,836,817 | 2,121,189* | 1,898,397 | 2,348,227 |
| Total operating expenses | 3,271,952 | 5,045,796.5 | 4,029,841 | 6,072,982 |
| Loss from operations | -3,271,952 | -5,045,796.5* | -4,029,841 | -6,072,982 |
| Gain on remeasurement of warrant liabilities | 0 | 114,045* | -27,816 | 11,126 |
| Interest expense | 6,653 | 2,299* | 2,605 | 4,797 |
| Interest income | 89,354 | 188,445* | 59,103 | 22,847 |
| Other expense, net | -3,390 | -20,024* | -6,774 | -1,850 |
| Total other income, net | 79,311 | 280,167* | 21,908 | 27,326 |
| Loss before provision for income taxes | -3,192,641 | -4,765,629.5* | -4,007,933 | -6,045,656 |
| Provision for income taxes | 3,346 | 2,698* | 2,840 | 7,954 |
| Net loss | -3,195,987 | -4,768,327.5 | -4,010,773 | -6,053,610 |
| Basic EPS | -0.46 | 0.043 | -0.06 | -0.12 |
| Basic Average Shares | 7,022,945 | -111,649,942 | 72,685,740 | 49,847,872 |
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)